Scandion Oncology’s technology is dedicated to developing new cancer treatments that will overcome chemotherapy resistance for thousands of patients.
Scandion Oncology has two major assets under development, SCO-101 and SCO-201, and more than 800 analogues for the future. The target indications for the analogues are solid tumors.
In addition, Scandion Oncology has access to a screening platform of drug resistant cancer cells. This platform screens for the ability of analogues to restore drug sensitivity.
Our most advanced asset, SCO-101, is a first-in-class oral compound that is currently in clinical Phase Ib and Phase II studies in cancer patients.
SCO-101 has previously shown a favourable safety profile in Phase I trials in healthy volunteers.
The target indications are metastatic colorectal cancer and inoperable or metastatic pancreatic cancer, with more indications likely to follow.
SCO-101 is protected by a broad patent estate owned by Scandion Oncology.
Our second asset, SCO-201, is an oral compound designed to reverse drug resistance by inhibition of an efflux pump.
The target indications will be within solid tumors.
SCO-201 is protected by a broad patent estate held by Scandion Oncology.